Evidence map›Paper›PMID 35740647›Full record

ArticleCancers2022

Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.

Yutaka Yasui, Masayuki Kurosaki, Kaoru Tsuchiya, Yuka Hayakawa, Chitomi Hasebe, Masami Abe, Chikara Ogawa, Kouji Joko, Hironori Ochi, Toshifumi Tada and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. [Chinese expert consensus on the use of standardized second-line drugs for primary hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 1 country.

Yutaka YasuiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan.ORCID 0000-0002-6117-4990
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan.ORCID 0000-0001-7016-8931
Kaoru TsuchiyaDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan.ORCID 0000-0003-0436-5915
Yuka HayakawaDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan.
Chitomi HasebeDepartment of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa 070-8530, Japan.
Masami AbeDepartment of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa 070-8530, Japan.
Chikara OgawaDepartment of Gastroenterology, Takamatsu Red Cross Hospital, Takamatsu 760-0017, Japan.ORCID 0000-0002-4534-6692
Kouji JokoCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama 790-8524, Japan.
Hironori OchiCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama 790-8524, Japan.
Toshifumi TadaDepartment of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Himeji 670-8540, Japan.
Shinichiro NakamuraDepartment of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Himeji 670-8540, Japan.
Koichiro FurutaDepartment of Internal Medicine, Masuda Red Cross Hospital, Masuda 698-8501, Japan.
Hiroyuki KimuraDepartment of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan.
Keiji TsujiDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima 730-8619, Japan.
Yuji KojimaDepartment of Gastroenterology, Japanese Red Cross Ise Hospital, Ise 516-8512, Japan.
Takehiro AkahaneDepartment of Gastroenterology, Ishinomaki Red Cross Hospital, Ishinomaki 986-8522, Japan.
Takashi TamadaDepartment of Gastroenterology, Takatsuki Red Cross Hospital, Takatsuki 569-1096, Japan.
Yasushi UchidaDepartment of Gastroenterology, Matsue Red Cross Hospital, Matsue 690-8506, Japan.
Masahiko KondoDepartment of Gastroenterology, Otsu Red Cross Hospital, Otsu 520-8511, Japan.
Akeri MitsudaDepartment of Internal Medicine, Japanese Red Cross Tottori Hospital, Tottori 680-8517, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan.
Japanese Red Cross Liver Study Group
Musashino Red Cross Hospital · JPHimeji Red Cross Hospital · JPJapanese Red Cross Asahikawa Hospital · JPMatsuyama Red Cross Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPIse Red Cross Hospital · JPKyoto first Red Cross hospital · JPMatsue Red Cross Hospital · JPOtsu Red Cross Hospital · JPTakamatsu Red Cross Hospital · JPTakatsuki Red Cross Hospital · JPTottori Prefectural Central Hospital · JPTsuda University · JP

Funding

Japan Agency for Medical Research and Development JP20fk0210067h0001Miyakawa Memorial Research Foundation noneUehara Memorial Foundation none
6 · The paper itself

Abstract

backgroundThe present study aimed to clarify the efficacy and safety of ramucirumab in a real-world setting, including patients who experienced two or more systemic treatments or whose hepatic reserve was deteriorated.

methodsIn total, 79 patients with hepatocellular carcinoma (HCC) from 14 institutes throughout Japan were retrospectively analyzed. The response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and AEs were recorded according to the Common Terminology Criteria for AEs (CTCAE) version 5.0.

resultsMedian overall survival (OS) in the total cohort was 7.5 months (m). Median OS was 8.8 m in patients who were administered ramucirumab as a second-line treatment, while it was 7.3 m in third- or later-line treatment. Progression-free survival rates in the second- and third- or later-line therapies were 3.2 m and 3.2 m, respectively. The disease control rate (DCR) in the study was 43%. There were no statistically significant differences in DCR between the treatment courses. Regarding adverse events (AEs), the development of ascites was observed significantly more frequently in modified albumin-bilirubin (mALBI) 2b/3 patients than in mALBI 1/2a patients (54.5% vs. 25.0%,

conclusionsRamucirumab is useful as a second-line therapy and feasible as a third- or later-line treatment for HCC.

Indexed as

hepatocellular carcinomamolecularly targeted agentsramucirumab

Identifiers

PMID35740647
PMCPMC9221496
OpenAlexW4283073359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.